Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Scientific Correspondence
  • Published:

Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden

Molecular Psychiatry volume 9, pages 547–549 (2004)Cite this article

SIR – The addictions are complex diseases whose onset, persistence, and treatment are influenced by interactions between genetic, environmental, and pharmacological factors.1 A study of 3372 twin pairs found that genetic, shared environmental, and nonshared environmental factors similarly influence the development of drug abuse and dependence.2 The authors also found that 54% of the total and 38% of the unique variance in heroin abuse were attributable to genetic factors.2

Mu-opioid receptor (OPRM1) gene polymorphisms are logical candidates for association studies in the addictive diseases.3 The endogenous opioid system is central to the function and modulation of physiological systems affected by all drugs of abuse.1 Quantitative trait locus studies and studies in OPRM1 knockout mice have confirmed the importance of this receptor to the rewarding effects of opiates and other drugs of abuse.4,5,6

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Kreek MJ et al. Nat Rev Drug Disc 2002; 1: 710–726.

  2. Tsuang MT et al. Arch Gen Psychiatry 1998; 55: 967–972.

    Article  CAS  Google Scholar 

  3. LaForge KS et al. Eur J Pharmacol 2000; 410(2): 249–268.

  4. Belknap JK et al. Ann NY Acad Sci 1992; 645: 311–323.

  5. Matthes HWD et al. Nature 1996; 383: 819–823.

    Article  CAS  Google Scholar 

  6. Becker A et al. Naunym-Schmiedebergs Arch Pharmacol 2000; 361: 584–589.

  7. Bond C et al. Proc Natl Acad Sci USA 1998; 95: 9608–9613.

  8. Wand GS et al. Neuropsychopharmacology 2002; 26: 106–114.

    Article  CAS  Google Scholar 

  9. Hernandez-Avila CA et al. Am J Med Genet 2003; 118B: 60–65.

  10. Oslin DW et al. Neuropsychopharmacology 2003; 28: 1546–1552.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY, USA

    G Bart, K S LaForge & M J Kreek

  2. Division of Psychiatry, NEUROTEC, Karolinska Institute, M57 Huddinge University Hospital, Stockholm, Sweden

    M Heilig, L Pollak & M J Kreek

  3. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA

    S M Leal

  4. The Laboratory of Statistical Genetics, The Rockefeller University, New York, NY, USA

    J Ott

Authors
  1. G Bart
    View author publications

    Search author on:PubMed Google Scholar

  2. M Heilig
    View author publications

    Search author on:PubMed Google Scholar

  3. K S LaForge
    View author publications

    Search author on:PubMed Google Scholar

  4. L Pollak
    View author publications

    Search author on:PubMed Google Scholar

  5. S M Leal
    View author publications

    Search author on:PubMed Google Scholar

  6. J Ott
    View author publications

    Search author on:PubMed Google Scholar

  7. M J Kreek
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to G Bart.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bart, G., Heilig, M., LaForge, K. et al. Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. Mol Psychiatry 9, 547–549 (2004). https://doi.org/10.1038/sj.mp.4001504

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.mp.4001504

This article is cited by

Search

Advanced search

Quick links